Connecting Aplastic anemia to Military Service
Blood and lymphatic disorders in veterans are frequently linked to toxic exposure during military service. Hematologic malignancies — including leukemia, lymphoma, and multiple myeloma — have well-established associations with radiation exposure, Agent Orange, benzene from jet fuels and industrial solvents, and burn pit particulates. Aplastic anemia may qualify for presumptive service connection under the PACT Act (2022), Agent Orange exposure presumptives for Vietnam-era veterans, or through documented occupational toxic exposure during service.
How VA Rates Aplastic anemia
The VA rates Aplastic anemia based on laboratory values and functional impairment. Active malignant hematologic conditions (leukemia, lymphoma, myeloma) are rated at 100% during active treatment and for six months following the completion of treatment. After treatment, residuals are rated based on ongoing functional impairment. Non-malignant hematologic disorders (anemia, thrombocytopenia, polycythemia) are rated based on hemoglobin/platelet levels, transfusion requirements, and the degree of systemic impairment.
Diagnostic Code: 7716 — Aplastic anemiais evaluated under 38 CFR Part 4 using this code. Ratings are determined at your Compensation & Pension (C&P) exam and confirmed in your rating decision letter.
Evidence Required for Your Aplastic anemia Claim
- Complete blood count (CBC) and differential, with all lab values from treating hematologist or oncologist
- Bone marrow biopsy results for hematologic malignancies
- Deployment records establishing service in Agent Orange, burn pit, or radiation exposure locations
- Occupational exposure records documenting benzene, solvent, or radiation exposures
- Treating hematologist or oncologist records and nexus letter
- PACT Act Airborne Hazards Registry documentation if applicable
Frequently Asked Questions — Aplastic anemia and VA Disability
How does VA rate Aplastic anemia?
Active hematologic malignancies are rated at 100% during treatment. After treatment completion, the rating drops to the residual level — typically rated based on ongoing blood count deficiencies, transfusion requirements, functional limitations, immunosuppression, and fatigue. Non-malignant blood disorders are rated on severity of anemia (hemoglobin levels), platelet counts, or bone marrow function. Your complete blood work and specialist notes are the most critical evidence.
Is Aplastic anemia connected to Agent Orange or PACT Act exposure?
Many hematologic malignancies have presumptive status under Agent Orange exposures (for Vietnam-era veterans) or the PACT Act (for burn pit-era veterans). Leukemia, Hodgkin's lymphoma, multiple myeloma, and non-Hodgkin's lymphoma all have Agent Orange presumptive status for eligible veterans. The PACT Act extended coverage to additional blood cancers for veterans with burn pit exposure histories. Presumptive claims do not require a nexus letter — exposure documentation plus current diagnosis is sufficient.
What evidence does VA need for a Aplastic anemia claim?
For hematologic malignancies: (1) pathology confirming diagnosis, (2) deployment or service records establishing qualifying toxic exposure for presumptive claims, (3) complete treatment records. For non-malignant conditions: (1) specialist diagnosis, (2) laboratory evidence of severity, (3) nexus letter from a hematologist. Establishing the effective date is critical for retroactive pay — file as early as possible even if your diagnosis is new.
Can Aplastic anemia be secondary to another service-connected condition?
Yes. Secondary hematologic conditions can arise from service-connected conditions whose treatments (chemotherapy, radiation, long-term medication use) caused hematologic side effects. Additionally, some hematologic conditions secondary to toxic exposure claims overlap with direct service connection through documented occupational exposure. A hematologist's nexus letter explaining the relationship between the primary condition and the blood disorder is required for secondary claims.